This mini-review discusses key clinical manifestations of APDS resulting from dysregulated PI3K pathway hyperactivity and focuses on the specific clinical management options for patients with APDS1 and APDS2 by considering the effects of modulating the PI3K-Akt-mTOR pathway. This evidence concerns the gene PIK3CA and activated PI3K-delta syndrome.